#MicroCosting
LightNews LightNews
iliasgoranitis.bsky.social
An important step towards the economic evaluation of #FunctionalGenomics! A #MicroCosting of mass-spectrometry based quantitative #Proteomics url.au.m.mimecastprotect.com/s/TeIxCxnMJ5... @ausgenomics.bsky.social
A micro-costing study of mass-spectrometry based quantitative proteomics testing applied to the diagnostic pipeline of mitochondrial and other rare disorders
url.au.m.mimecastprotect.com
December 1, 2024 at 6:47 AM
ephresearchcentre.bsky.social
NEW PUBLICATION

Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study

Liz Morrell, AI-REAL Consortium, Sarah Wordsworth

www.sciencedirect.com/science/arti...

@oxpop.bsky.social
Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study
Determining the cost of diagnosis of Burkitt lymphoma by DNA sequencing from a blood sample, compared with current histopathology. Estimating future s…
www.sciencedirect.com
April 10, 2025 at 1:16 PM
ihea-econ-omics.bsky.social
(7/9)
• Goranitis, I., et al. The GUV Scale. Value in Health, 2025.
• Peters, R., et al. Public preferences for genomic newborn screening. Am J Hum Genet, 2025.
• Santos Gonzalez, F., et al. Microcosting genomics: Challenges & opportunities. Genetics in Medicine, 2025.
January 26, 2026 at 5:30 PM
untilorg.bsky.social
Preventing HIV among the people at highest risk of acquiring it may cost far less than many public health agencies fear.

bioengineer.org/microcosting...
Microcosting PrEP optimization for sexual and gender minorities with
Preventing HIV among the people at highest risk of acquiring it may cost far less than many public health agencies fear. A new economic analysis, published in Addiction Science & Clinical
bioengineer.org
September 2, 2026 at 4:59 PM
medrxivpreprint.bsky.social
Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia https://www.medrxiv.org/content/10.1101/2023.09.04.23295012v1
Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia https://www.medrxiv.org/content/10.1101/2023.09.04.23295012v1
Introduction Genomic testing is a relatively new, disruptive and complex health technology with mult
www.medrxiv.org
September 4, 2023 at 3:41 PM
gimjournal.bsky.social
Are #GenomicSequencing costs actually decreasing? #Microcosting studies are vital for understanding the economic cost, but challenges persist in quality, consistency, and comparability of studies bit.ly/4fVHC5t #HealthcareEconomics
Screenshot of text that reads: Challenge 2: Disaggregation and sourcing of resource use and unit prices The disaggregation of costs requires a comprehensive mapping of the entire sequencing process. Clinical ES and GS involve multiple stages that may be carried out by different laboratory departments or even outsourced to third parties, as is the case with sequencing. This complicates the identification of appropriate unit costs and resource use items for measurement and valuation. Simply aggregating cost data from various sources might not be reliable if differences in protocols and associated resources utilized between various laboratories are not considered. Accurately measuring costs requires detailed delineation of the sequencing workflow to include all stages, from preanalytic sample collection to postanalytic generation of the test report. This should reflect all steps and work teams involved, accounting for factors such as sample processing volumes, sequencing methods, equipment, and validation procedures, indicating when steps are outsourced and how these were costed (eg, market price or supplier-negotiated prices). This approach better reflects practice across laboratory departments and providers, resulting in a more accurate estimation of costs and resources.
January 10, 2025 at 8:34 PM